Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryViva Health Radicava (edaravone) Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0305

    Radicava (edaravone) — Intravenous

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0305 alerts

    Get alerted when Policy IC-0305 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, dosing limits, clinical criteria, and billing for intravenous edaravone (Radicava) for treatment of amyotrophic lateral sclerosis (ALS) for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyRadicava (edaravone) — Intravenous
    Policy CodePolicy IC-0305
    Change TypeAnnual review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approval valid 180 days, renewals up to 365 days.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    180dinitial prior authorization validity
    365drenewal prior authorization validity
    %FVC ≥80%pulmonary function threshold
    ≥18minimum age
    J1301

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS code
    N/AMedicare Part B codes

    Coverage Criteria for Radicava (edaravone)

    Initial Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Initial criteria: Member is at least 18 years of age; AND will not be used in combination with other formulations of edaravone (e.g., oral); AND member has a diagnosis of clinically definite or probable amyotrophic lateral sclerosis (ALS) based on El Escorial revised criteria, Gold Coast criteria, or Awaji criteria; AND disease duration is 2 years or less; AND percent-predicted forced vital capacity (%FVC) is >= 80%; AND baseline documentation demonstrates retained functionality for most activities of daily living, defined as a score of 2 or better on each individual item of the ALSFRS-R.age >= 18; disease duration <= 2 years; %FVC >= 80%; ALSFRS-R item score >= 2

    Continuation Therapy / Renewal — Renewal allowed when ALL of the following are met:

    Renewal is allowed when ALL of the following are met:

    Renewal criteria: Member continues to meet the universal and indication-specific criteria from initial approval; AND absence of unacceptable toxicity from the drug (examples: hypersensitivity reactions, anaphylaxis, sulfite allergic reactions); AND member has responded to therapy compared to pretreatment baseline with disease stability or mild progression indicating a slowing of decline on the ALSFRS-R (no rapid disease progression while on therapy); AND member does not have a cumulative ALSFRS-R score of <= 3.ALSFRS-R cumulative score > 3; evidence of stability or slowed decline; no unacceptable toxicity

    Use of Radicava (intravenous edaravone) in combination with other formulations of edaravone (for example, oral edaravone) is excluded and will not be authorized.

    Appendix — Medicare Part B covered diagnosis codes: N/A. There are no specific Medicare Part B covered diagnosis codes listed for this therapy in the appendix.

    Treatment is not supported when the member fails to meet required clinical criteria, including a diagnosis of clinically definite or probable ALS by El Escorial/Gold Coast/Awaji criteria, disease duration > 2 years, or percent-predicted forced vital capacity below the required threshold. Baseline functional requirements must also be met (ALSFRS-R item scores of 2 or better on each item); lack of these baseline measures or evidence of unacceptable toxicity or absence of response (no stability or slowed decline on ALSFRS-R) will preclude authorization or continuation.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J1301Injection, edaravone, 1 mg; 1 billable unit = 1 mg
    Covered ICD-10 Diagnosis CodesICD-10Covered
    G12.21Amyotrophic lateral sclerosis
    NDCNDC
    70510-2171-xxRadicava 30 mg/100 mL single-dose bag (NDC)
    Covered ICD-10 Diagnosis CodesICD-10Covered
    G12.21Amyotrophic lateral sclerosis
    Medicare Part B Covered Diagnosis CodesICD-10
    No codes listed
    inv-11: Initial dosing regimen
    Initial dosing regimen60 mg IV once daily for 14 consecutive days followed by 14 days off (initial treatment cycle).
    Route and infusion timeIntravenous infusion over 60 minutes per dose.
    Initial cycle patternDaily x14 days then 14-day drug-free period (per 28-day cycle).
    inv-12: Subsequent dosing limit per 28 days
    Subsequent dosing limitMaximum 600 billable units (J1301 units) per 28-day cycle for subsequent dosing.
    Unit definition

    Provider Actions, Documentation, and Denial Risks

    Prior Authorization

    Obtain prior authorization — note validity periods

    Prior authorization is required for Radicava (edaravone). Initial authorizations are valid for 6 months (180 days); renewals may be issued for up to 12 months (365 days).

    • Initial: 6 months (180 days)
    • Renewal: up to 12 months (365 days)
    Note

    Follow Medicare Benefit Policy Manual and applicable NCDs/LCDs/LCAs

    When making preauthorization or coverage determinations for outpatient drug claims under Part B, follow the Medicare Benefit Policy Manual, Chapter 15 §50 and any applicable NCDs, LCDs, and LCAs; compliance with those Medicare policies is required where applicable.

    Background

    Edaravone (Radicava) is an intravenous free radical scavenger approved by the FDA for the treatment of amyotrophic lateral sclerosis (ALS). This policy applies to use of IV edaravone in members with clinically definite or probable ALS who are early in their disease course, have preserved respiratory function (percent-predicted FVC threshold required by the policy), and demonstrate retained baseline activities of daily living as documented by the ALSFRS-R.

    Definitions and Scales

    inv-24: ALSFRS-R — ALS Functional Rating Scale - Revised
    Instrument nameALS Functional Rating Scale - Revised (ALSFRS-R).
    Structure12-item questionnaire covering bulbar, fine motor, gross motor, and respiratory domains; each item scored 0–4; total possible score 48.
    Baseline requirementBaseline documentation must show retained functionality (score of ≥2 on each individual ALSFRS-R item) for initial coverage.
    inv-25: Clinically definite or probable ALS
    Diagnostic criteria acceptedClinically definite or probable ALS diagnosed per El Escorial revised criteria, Gold Coast criteria, or Awaji criteria.
    Role in coverageDiagnosis per these criteria is required for initial prior authorization approval.

    Revision History

    2026-07-01policy_reviewLatest

    Policy last reviewed and document updated with current coverage criteria and administrative details; effective and last review date recorded as 2026-07-01.

    medicare_guidance_note

    Medicare Part B coverage and determinations must follow Medicare Benefit Policy Manual, Chapter 15 §50 and any applicable NCDs/LCDs/LCAs; plan information is intended for non‑Medicare determinations and CMS guidance must be followed where applicable.

    Policy Summary
    PayerViva Health
    PolicyRadicava (edaravone) — Intravenous
    Policy CodePolicy IC-0305
    Change TypeAnnual review — no material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization: initial approval valid 180 days, renewals up to 365 days.
    SourceLink
    On This Page
    Coverage Criteria for Radicava (edaravone)Billing and CodingProvider Actions, Documentation, and Denial RisksBackgroundDefinitions and ScalesRevision History
    HCPCS J1301 = Injection, edaravone, 1 mg; 1 billable unit = 1 mg.
    Cycle basisLimit applies to each 28-day treatment cycle after the initial cycle.
    inv-13: Pulmonary threshold
    Pulmonary function requirementPercent-predicted forced vital capacity (%FVC) must be ≥ 80% for initial coverage.
    Measurement context%FVC is assessed at baseline as part of initial approval criteria.
    Renewal considerationMaintaining adequate respiratory function is required; unacceptable decline may affect renewal eligibility.
    inv-26: G12.21 = Amyotrophic lateral sclerosis (definition reiterated in coding)
    ICD-10 codeG12.21
    DescriptionAmyotrophic lateral sclerosis (ALS).
    Use on claimsInclude G12.21 on claims for Radicava as the covered diagnosis code in Appendix 1.
    Step Therapy

    Do not combine with other edaravone formulations

    Do not prescribe or administer Radicava in combination with other formulations of edaravone (for example, oral edaravone). Use with other edaravone formulations is excluded.

    Note
    Documentation Required

    Provide required clinical documentation at initial request

    Include documentation that the member meets diagnostic and baseline clinical thresholds: a diagnosis of clinically definite or probable ALS (El Escorial/Gold Coast/Awaji criteria), disease duration ≤ 2 years, baseline percent-predicted FVC (%FVC) ≥ 80%, and baseline ALSFRS-R item scores of 2 or better (documenting retained functionality).

    • Diagnosis per El Escorial, Gold Coast, or Awaji criteria
    • Disease duration ≤ 2 years
    • Baseline %FVC ≥ 80%
    • Baseline ALSFRS‑R item score ≥ 2 on each item
    Billing Rule

    Include ICD-10 diagnosis code G12.21 on claims

    Include the appropriate diagnosis code on claims: use ICD-10 code G12.21 (Amyotrophic lateral sclerosis) as listed in Appendix 1 for Radicava (edaravone).

    • ICD-10: G12.21 = Amyotrophic lateral sclerosis
    Denial Risk

    Risk of denial for unacceptable toxicity or lack of clinical benefit

    Be aware that renewal or continuation may be denied if the member experiences unacceptable toxicity from the drug (examples: hypersensitivity reactions, anaphylaxis, sulfite allergic reactions) or if there is lack of clinical benefit at renewal (no stability or slowed decline on ALSFRS‑R).

    • Examples of unacceptable toxicity: hypersensitivity reactions, anaphylaxis, sulfite allergic reactions
    • Lack of response (no stability or slowed decline on ALSFRS‑R) may prompt denial
    Denial Risk

    Risk of denial for failure to meet clinical criteria

    Requests may be denied if the member does not meet initial or renewal clinical criteria — including documented diagnosis, disease duration ≤ 2 years, required %FVC threshold, or baseline functional ALSFRS‑R requirements.

    • Failure to document diagnosis per required criteria
    • Disease duration > 2 years
    • %FVC below required threshold
    • Baseline ALSFRS‑R item scores not meeting minimums
    Note

    Comply with applicable Medicare NCDs/LCDs/LCAs to avoid denial

    Ensure claims and authorization decisions for Part B drugs comply with applicable Medicare NCDs, LCDs, and LCAs; noncompliance with those Medicare policies where they apply may result in claim denial.

    Disease duration contextUsed alongside disease duration (≤2 years) and functional/pulmonary thresholds to determine eligibility.
    inv-26: G12.21 — Amyotrophic lateral sclerosis (ICD-10 code definition)
    ICD-10 codeG12.21
    Short descriptionAmyotrophic lateral sclerosis
    Appendix referenceListed in Appendix 1 as the covered diagnosis code for Radicava (edaravone).